Literature DB >> 83485

Physostigmine in Alzheimer's disease.

C M Smith, M Swash.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 83485     DOI： 10.1016/s0140-6736(79)90479-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Physostigmine for Alzheimer's disease.

Authors:  F Coelho; J Birks
Journal:  Cochrane Database Syst Rev       Date:  2001

Review 2.  Cholinesterases and the fine line between poison and remedy.

Authors:  Carey N Pope; Stephen Brimijoin
Journal:  Biochem Pharmacol       Date:  2018-01-31       Impact factor: 5.858

3.  Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease.

Authors:  O Muramoto; M Sugishita; K Ando
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-05       Impact factor: 10.154

4.  The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro.

Authors:  A J Hunter; T K Murray; J A Jones; A J Cross; A R Green
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

5.  The noradrenergic system in Alzheimer and multi-infarct dementias.

Authors:  D M Mann; P O Yates; J Hawkes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-02       Impact factor: 10.154

6.  Relation of brain regional physostigmine concentration to cholinesterase activity and acetylcholine and choline levels in rat.

Authors:  M Hallak; E Giacobini
Journal:  Neurochem Res       Date:  1986-07       Impact factor: 3.996
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.